| (24S)-24-hydroxycholesterol | increases metabolic processing | ISO | RGD:1316686 | 6480464 | CYP39A1 protein results in increased metabolism of 24-hydroxycholesterol | CTD | PMID:10748047 |
| 1H-pyrazole | decreases expression | ISO | RGD:1316686 | 6480464 | pyrazole results in decreased expression of CYP39A1 mRNA | CTD | PMID:17945193 |
| 2,2',4,4',5,5'-hexachlorobiphenyl | increases expression | ISO | RGD:1316686 | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of CYP39A1 mRNA | CTD | PMID:21851831 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1316685 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP39A1 mRNA | CTD | PMID:20106945 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of CYP39A1 mRNA | CTD | PMID:22298810 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1316686 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CYP39A1 mRNA | CTD | PMID:19770486 |
| 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2,4-dinitrotoluene affects the expression of CYP39A1 mRNA | CTD | PMID:21346803 |
| aflatoxin B1 | affects expression | ISO | RGD:1316685 | 6480464 | Aflatoxin B1 affects the expression of CYP39A1 protein | CTD | PMID:20106945 |
| aflatoxin B1 | decreases expression | ISO | RGD:1316685 | 6480464 | Aflatoxin B1 results in decreased expression of CYP39A1 mRNA | CTD | PMID:22100608 |
| aflatoxin B1 | decreases expression | ISO | RGD:1316686 | 6480464 | Aflatoxin B1 results in decreased expression of CYP39A1 mRNA | CTD | PMID:19770486 |
| all-trans-retinoic acid | increases expression | ISO | RGD:1316685 | 6480464 | Tretinoin results in increased expression of CYP39A1 mRNA | CTD | PMID:21934132 |
| arsenite(3-) | decreases expression | ISO | RGD:1316686 | 6480464 | arsenite results in decreased expression of CYP39A1 mRNA | CTD | PMID:18929588 |
| benzo[a]pyrene | increases expression | ISO | RGD:1316685 | 6480464 | Benzo(a)pyrene results in increased expression of CYP39A1 mRNA | CTD | PMID:16545412 |
| benzo[a]pyrene | multiple interactions | ISO | RGD:1316686 | 6480464 | AHR protein affects the reaction [Benzo(a)pyrene affects the expression of CYP39A1 mRNA] | CTD | PMID:22228805 |
| benzo[a]pyrene | decreases expression | ISO | RGD:1316686 | 6480464 | Benzo(a)pyrene results in decreased expression of CYP39A1 mRNA | CTD | PMID:19770486 PMID:22228805 |
| benzo[a]pyrene | decreases expression | ISO | RGD:1316686 | 6480464 | Benzo(a)pyrene results in decreased expression of CYP39A1 mRNA | CTD | PMID:19770486 |
| cadmium sulfate | multiple interactions | ISO | RGD:1316686 | 6480464 | cadmium sulfate affects the reaction [MTF1 affects the expression of CYP39A1 mRNA] | CTD | PMID:16221973 |
| carbamazepine | increases expression | ISO | RGD:1316685 | 6480464 | Carbamazepine results in increased expression of CYP39A1 mRNA | CTD | PMID:17112801 |
| chloroprene | increases expression | ISO | RGD:1316686 | 6480464 | Chloroprene results in increased expression of CYP39A1 mRNA | CTD | PMID:23125180 |
| choline | multiple interactions | ISO | RGD:1316686 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CYP39A1 mRNA | CTD | PMID:20938992 |
| ciguatoxin CTX1B | affects expression | ISO | RGD:1316686 | 6480464 | Ciguatoxins affects the expression of CYP39A1 mRNA | CTD | PMID:18353800 |
| cyclosporin A | decreases expression | ISO | RGD:1316685 | 6480464 | Cyclosporine results in decreased expression of CYP39A1 mRNA | CTD | PMID:20106945 |
| diarsenic trioxide | decreases expression | ISO | RGD:1316685 | 6480464 | arsenic trioxide results in decreased expression of CYP39A1 mRNA | CTD | PMID:15761015 |
| ethanol | increases expression | ISO | RGD:1316686 | 6480464 | Ethanol results in increased expression of CYP39A1 mRNA | CTD | PMID:19167417 |
| folic acid | multiple interactions | ISO | RGD:1316686 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CYP39A1 mRNA | CTD | PMID:20938992 |
| L-methionine | multiple interactions | ISO | RGD:1316686 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CYP39A1 mRNA | CTD | PMID:20938992 |
| phenobarbital | affects expression | ISO | RGD:1316686 | 6480464 | Phenobarbital affects the expression of CYP39A1 mRNA | CTD | PMID:23091169 |
| pirinixic acid | multiple interactions | ISO | RGD:1316686 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CYP39A1 mRNA | CTD | PMID:19710929 |
| pirinixic acid | multiple interactions | ISO | RGD:1316686 | 6480464 | PPARA protein inhibits the reaction [pirinixic acid results in increased expression of CYP39A1 mRNA] | CTD | PMID:17950772 |
| pirinixic acid | decreases expression | ISO | RGD:1316686 | 6480464 | pirinixic acid results in decreased expression of CYP39A1 mRNA | CTD | PMID:20813756 |
| pirinixic acid | increases expression | ISO | RGD:1316686 | 6480464 | pirinixic acid results in increased expression of CYP39A1 mRNA | CTD | PMID:17950772 |
| pirinixic acid | multiple interactions | ISO | RGD:1316685 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of CYP39A1 mRNA | CTD | PMID:19710929 |
| tetrachloromethane | increases expression | ISO | RGD:1316686 | 6480464 | Carbon Tetrachloride results in increased expression of CYP39A1 mRNA | CTD | PMID:17484886 |
| tunicamycin | decreases expression | ISO | RGD:1316686 | 6480464 | Tunicamycin results in decreased expression of CYP39A1 mRNA | CTD | PMID:17127020 |
| valproic acid | affects expression | ISO | RGD:1316686 | 6480464 | Valproic Acid affects the expression of CYP39A1 mRNA | CTD | PMID:17292431 |